The high cost of medication, stigmatisation and poor acceptance of their condition are causing young adults to take a dangerous approach to managing their asthma, according to new research published today in the journal BMJ Open.
In the UK 5.4 million people are currently receiving treatment for asthma: 1.1 million children (one in 11) and 4.3 million adults (one in 12). There were 1,131 deaths from asthma in the UK in 2009. Most asthma deaths are preventable.
Despite the availability of effective treatments, poor asthma control is common.
The overuse of short-acting bronchodilators ("quick-acting" inhalers, usually blue, which relieve acute asthma symptoms) is a marker of poor asthma control and is linked to increased risk of hospital admission and death from asthma.
Regular use of low dose anti-inflammatory corticosteroid inhalers (preventer inhalers, usually brown) are fundamental to successfully controlling asthma, and preventing asthma symptoms.
In this study, led by Queen Mary, University of London, researchers looked at why young adults (20yrs -32yrs) overuse short-acting bronchodilators. The researchers interviewed 21 young adults from the same urban general practice who were classed as either high users (12) or low users (nine) of short-acting bronchodilators as judged by their number of prescriptions. They found:
-
Cost was seen as a major disincentive to obtaining preventive medication
-
High-users were more likely to express anger or resentment at their condition
-
High-users often reported poor control of their asthma symptoms
-
Stigma was common, with inhalers described as something "to hide in a bag"
Chris Griffiths, Professor of Primary Care at Queen Mary, who led the research said: "Relying on short-acting bronchodilators - 'my blue (inhaler) takes a battering' as one patient put it - is not a safe way to manage asthma and individuals taking this approach are putting their lives and health at risk.